Trial
NCT03116971
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Small Cell Lung Cancer
Intervention
M3814
Why stopped
Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-16